Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiodarone for Prevention of NOAF After TAVI
NCT03991754Phase 3Completed
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amiodarone in Atrial fibrillation (AFib) (2 arms). Primary endpoint: Incidence of new onset atrial fibrillation at 30 days. Started Jan 2020; status: completed.
02
Drugs
amiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03991754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991754.